Creoptix Supporting COVID-19 Research

We are committed to enabling hospitals and clinical researchers with high performance solutions to characterise binding affinity and kinetics of antibodies on SARS-CoV-2 in conditions closer to real-life. The WAVE system's combination of sensitivity and robustness may prove crucial in shedding light on antibody binding in serum and plasma,” said our CEO at an interview with Private Equity Wire. 
 
More information here
Last modified onFriday, 19 June 2020 17:58